Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Held the 14th general shareholders' meeting
22
2024.03
Kangstem Biotech's 14th shareholder's meeting held on the 21rd.
Kangstem Biotech's 14th shareholder's meeting held on the 21rd.
Thanks to the support of shareholders, all of the company's agenda items were approved.
After the meeting, followed by a Q&A session with shareholders on the progress and future schedule of clinical trials for the company's main pipeline, atopic dermatitis and osteoarthritis dermatitis.